Onset and Duration of Action of Ketotifen 0.025% and Emedastine 0.05% in Seasonal Allergic Conjunctivitis
Tóm tắt
Objective: To compare the efficacy, onset and duration of action, and the safety of ketotifen fumarate 0.025% ophthalmic solution and emedastine difumarate 0.05% ophthalmic solution in subjects with seasonal allergic conjunctivitis (SAC) induced by allergen exposure, using the Vienna Challenge Chamber model.
Design and setting: This was a double-masked, randomised, comparative, crossover study conducted at an allergy outpatient clinic in Austria.
Study participants: Subjects with an allergy to grass pollen were exposed to the allergen in a pollen chamber for 4 hours, followed by a 3-hour break and then a second exposure for 3 hours.
Interventions: Study participants were randomised to a treatment sequence (ketotifen followed by emedastine or emedastine followed by ketotifen), receiving 1 drop per eye of ketotifen or emedastine 2 hours after the initial allergen exposure in the pollen chamber.
Outcomes: Individual and composite ocular, individual and composite nasal, and total (ocular + nasal) symptom complex scores were determined by repeated exposure to allergen 0–2 hours and 5–8 hours after dosing. Onset of action was defined as the time to the first observation of a 20% reduction from baseline in the composite ocular symptom score.
Results: All 37 subjects enrolled completed the study. The median time to onset of action was 15 minutes for ketotifen and 30 minutes for emedastine. This difference was significant using the generalised linear model (p = 0.048), but not for the log-rank test analysis. In the initial 2 hours post dose, ketotifen provided significantly greater relief of both composite ocular symptoms (p = 0.026) and total symptom complex (p = 0.014). Both medications were effective in reducing symptoms 5 to 8 hours after dosing. No adverse events were reported for either treatment.
Conclusions: In the Vienna Challenge Chamber model, ketotifen and emedastine both effectively alleviated ocular symptoms of SAC after single-dose administration. Ketotifen had a faster onset of action and provided better symptom relief than emedastine during the first 2 hours after dosing. The rapid onset of action and symptom control make ketotifen a valuable treatment for SAC.
Tài liệu tham khảo
Weeke ER. Epidemiology of hay fever and perennial allergic rhinitis. Monogr Allergy 1987; 21: 1–20
Bielory L. Allergic and immunologic disorders of the eye: Part II. Ocular allergy. J Allergy Clin Immunol 2000; 106: 1019–32
Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994; 93: 413–23
Bonini S, Lambiase A, Juhas T, et al. Allergic conjunctivitis. Dev Ophthalmol 1999; 30: 54–61
Abelson MB, Schaefer K. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Surv Ophthalmol 1993; 38 Suppl. 3: 115–32
Grant SM, Goa KL, Fitton A, et al. Ketotifen: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs 1990; 40: 412–48
Nabe M, Miyagawa H, Agrawal DK, et al. The effect of ketotifen on eosinophils as measured at LTC4 release and by chemotaxis. Allergy Proc 1991; 12: 267–71
Gomes PJ, Welch DL, Abelson MB. Evaluation of the efficacy and safety of ketotifen fumarate in the allergen challenge model [abstract]. Invest Ophthalmol Vis Sci 2000; 41: S926
Fsadni MG, Lanz R, Taylor HR, et al. Efficacy and safety of ketotifen fumarate eye drops versus vehicle placebo and levocabastine in an environmental study of patients with seasonal allergic conjunctivitis [abstract]. Invest Ophthalmol Vis Sci 2000; 41: S368
Sharif NA, Su SX, Yanni JM. Emedastine: a potent, high affinity histamine H1-receptor-selective antagonist for ocular use: receptor binding and second messenger studies. J Ocul Pharmacol 1994; 10: 653–64
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects [online]. Available from URL: www.wma.net/e/policy/17-c_e/html. [Accessed October 2000]
Discepola M, Deschenes J, Abelson M. Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitis. Acta Ophthalmol Scand Suppl 1999; 228: 43–6
Netland PA, Leahy C, Krenzer KL. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model. Am J Ophthalmol 2000; 130: 717–23
Secchi A, Leonardi A, Discepola M, et al. An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05%: reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis. Emadine Study Group. Acta Ophthalmol Scand Suppl 2000; 230: 48–51
Verin P, Easty DL, Secchi A, et al. Clinical evaluation of twice-daily emedastine 0.05% eye drops (emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis. Am J Ophthalmol 2001; 131: 691–8
Horak F, Jager S. Die Wiener Provokationskammer (Vienna Challenge Chamber). Eine neue Methode des Allergenexpositiontests. Wien Klin Wochenschr 1987; 99: 509–10
Cartier A, Bernstein IL, Burge PS, et al. Guidelines for bronchoprovocation on the investigation of occupational asthma. Report of the Subcommittee on Bronchoprovocation for Occupational Asthma. J Allergy Clin Immunol 1989; 84: 823–9
Horak F, Stubner P, Zieglmayer R, et al. Effects of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002; 109(6): 956–61
Horak F, Stubner P, Zieglmayer R, et al. Controlled comparison of the efficacy and safety of cetirizine 10mg o.d. and fexofenadine 120mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001; 125(1): 73–0
Arnoux B, Denjean A, Page CP, et al. Accumulation of platelets and eosinophils in baboon lung after paf-acether challenge. Inhibition by ketotifen. Am Rev Respir Dis 1988; 137: 855–60
Sanjar S, Aoki S, Boubekeur K, et al. Inhibition of PAF-induced eosinophil accumulation in pulmonary airways of guinea pigs by anti-asthma drugs. Jpn J Pharmacol 1989; 51: 167–72
D’Arienzo PA, Leonardi A, Bensch G. Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther 2002; 24: 409–16